Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent
Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights - Continued to advance the development of CLD-401 towards the clinic - Presented new CLD-401 data and in situ TCE platform advances at the ESMO Congress 2026 - Received
How this was made
The 30-second read
Why it matters
This 8-K updates investors on quarterly losses, cash position, cost reductions, a restructuring plan targeting $3M annualized savings, and new preclinical poster data plus a small ATM registered direct offering.
Market read
Traders can reassess near-term dilution risk and sentiment around preclinical progress based on the financing, restructuring savings, and ESMO poster data.
What to watch
Cash fell to $3.9M (vs $5.6M at Dec 31), and the lead program remains IND-enabling with a stated first-patient plan in 2H 2027, leaving long execution risk.
Background
Calidi is a biotech developing the RedTail platform, including lead candidate CLD-401, and in situ T-cell engager candidates (CLD-501, CLD-502).
Ticker impact
Calidi reports Q3 2026 results, a $1.2M ATM registered direct offering, and new preclinical CLD-401 and TCE platform data at ESMO.
Shares may see modest upside bias as investors price in extended runway and fresh preclinical validation, tempered by limited cash and ongoing IND-enabling timeline.
The filing is a primary 8-K with quarterly financials plus a small gross raise and new preclinical posters; however, it does not provide clinical efficacy or FDA/regulatory milestones that would typically drive a large repricing.
Market effects
Adds incremental datapoints for targeted genetic medicines and oncolytic virus/TCE platform narratives, but no broad sector repricing signal.
No clear regional market linkage beyond biotech risk appetite.
Primarily US-listed microcap biotech-specific; limited spillover to global markets.
Counterpoint
The $1.2M gross ATM proceeds are small relative to ongoing cash needs, so the runway extension may not materially change the probability of future dilutive financing.
Key entities
- companyCalidi Biotherapeutics, Inc.
NYSE American-listed biotech (CLDI) reporting Q3 2026 financial results and recent business highlights.
- pipeline_programCLD-401
Lead RedTail candidate; preclinical posters reported complete tumor eradication in 80% of EMT6 breast cancer mice and activity in MB49 bladder model with systemic or intratumoral dosing.
- pipeline_programCLD-501 and CLD-502
In situ TCE candidates targeting TROP-2 and EpCAM; reported tumor-local EpCAM-targeted TCE generation and antigen-dependent cytotoxicity.
- financingAt-the-market registered direct offering
Gross proceeds of $1.2M, closed Sept 18, 2026.
- corporate_actionRestructuring plan
Executed Nov 6, 2026, expected to save $3M annualized via headcount reduction to extend cash runway.
